Zacks: Analysts Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.50 Per Share
Wall Street analysts expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to post earnings per share of ($0.50) for the current quarter, according to Zacks. Zero analysts have issued estimates for Spring Bank Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.51). Spring Bank Pharmaceuticals posted earnings of ($0.47) per share in the same quarter last year, which suggests a negative year over year growth rate of 6.4%. The firm is expected to announce its next earnings report on Tuesday, February 19th.
According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($1.81) per share for the current financial year, with EPS estimates ranging from ($1.89) to ($1.75). For the next financial year, analysts expect that the company will post earnings of ($2.17) per share, with EPS estimates ranging from ($2.40) to ($1.90). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Thursday, October 25th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.01.
NASDAQ:SBPH traded up $0.01 during mid-day trading on Friday, hitting $11.36. The company’s stock had a trading volume of 8,900 shares, compared to its average volume of 16,188. Spring Bank Pharmaceuticals has a 1 year low of $8.14 and a 1 year high of $15.95. The firm has a market cap of $194.16 million, a price-to-earnings ratio of -6.07 and a beta of 0.91.
Several hedge funds have recently bought and sold shares of the company. Jennison Associates LLC purchased a new position in Spring Bank Pharmaceuticals in the 3rd quarter valued at about $8,210,000. BlackRock Inc. lifted its stake in Spring Bank Pharmaceuticals by 1,498.8% in the 2nd quarter. BlackRock Inc. now owns 483,258 shares of the company’s stock valued at $5,727,000 after buying an additional 453,032 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Spring Bank Pharmaceuticals by 64.3% in the 3rd quarter. Baker BROS. Advisors LP now owns 613,144 shares of the company’s stock valued at $7,388,000 after buying an additional 240,000 shares in the last quarter. Sofinnova Ventures Inc purchased a new position in Spring Bank Pharmaceuticals in the 3rd quarter valued at about $2,285,000. Finally, Vanguard Group Inc lifted its stake in Spring Bank Pharmaceuticals by 34.8% in the 3rd quarter. Vanguard Group Inc now owns 549,186 shares of the company’s stock valued at $6,618,000 after buying an additional 141,730 shares in the last quarter. 42.84% of the stock is currently owned by institutional investors and hedge funds.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
Recommended Story: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.